Navigation Links
MabThera Significantly Increases Survival of Lymphoma Patients,Regardless of Chemotherapy Regimen

Data published today in the Journal of the National Cancer Institute

BASEL, Switzerland, 2 May 2007 - In a study published today in the Journal of the National Cancer Institute, the innovative cancer drug MabThera was shown to improve overall survival in patients with lymphoma regardless of the chemotherapy regimen used.1 The review further stated that the improvement in survival was seen for the first time in patients with mantle cell lymphoma, a rare, aggressive form of lymphoma.

The study was a comprehensive, systematic meta-analysis review of newly-diagnosed or relapsed patients involved in trials that compared MabThera treatment regimens with chemotherapy alone. The review not only demonstrated improved overall survival with MabThera but also that disease control in the MabThera containing arms of the trials was significantly superior to chemotherapy alone.

"This meta analysis clearly demonstrates the contribution MabThera makes to the management of patients with indolent lymphoma," commented Prof. Andreas Engert, from the Cochrane Hematological Malignacies Group, University of Cologne, and one of the authors of the study. "The results confirm the addition of MabThera to treatment of patients with two major forms of NHL extends patients' lives, regardless of their chemotherapy regimen."

Non-Hodgkin's lymphoma (NHL) affects 1 million people worldwide. It is estimated that 360,000 people die each year from the disease.2 Indolent NHL, representing about 45% of NHL patients, is a slow developing but serious cancer of the lymphatic system.

About the study The study included only randomized controlled trials (RCT) comparing R-chemo with chemotherapy alone in patients with newly diagnosed or relapsed indolent lymphoma and mantle cell lymphoma (MCL). Medical databases (Cochrane Library, MEDLINE, EMBA SE) and conference proceedings were searched (1990-2005). The study included full-text and abstract publications. Number needed to treat (NNT) were calculated to facilitate interpretation.

About MabThera

MabThera is a therapeutic antibody that binds to a particular protein - the CD20 antigen - on the surface of normal and malignant B-cells. It then recruits the body's natural defences to attack and kill the marked B-cells. Stem cells (B-cell progenitors) in bone marrow lack the CD20 antigen, allowing healthy B-cells to regenerate after treatment and return to normal levels within several months.

MabThera is indicated for the treatment of indolent and aggressive Non-Hodgkin's Lymphoma. MabThera is known as Rituxan in the United States, Japan and Canada. To date, patients have received more than 1 million treatments with MabThera worldwide.

Genentech and Biogen Idec co-market MabThera in the United States, and Roche markets MabThera in the rest of the world, except Japan, where MabThera is co-marketed by Chugai and Zenyaku Kogyo Co. Ltd.

About Roche

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, a market leader in virology and active in other major therapeutic areas such as autoimmune diseases, inflammation, metabolism and central nervous system. In 2006 sales by the Pharmaceuticals Division totalled 33.3 billion Swiss francs, and the Diagnostics Division posted sales of 8.7 billion Swiss francs. Roche employs roughly 75,000 worldwide and has R&D a greements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai. Additional information about the Roche Group is available on the Internet at www.roche.com <http://www.roche.com/> .

All trademarks used or mentioned in this release are protected by law.

References:

1 Schulz H et al. Immunochemotherapy With Rituximab and Overall Survival in Patients With Indolent or Mantle Cell Lymphoma: A Systematic Review and Meta-analysis. Journal of the National Cancer Institute 2007;99(8):706-714

2 Ferlay J, Bray F, Pisani P and Parkin D.M. GLOBOCAN 2002; Cancer Incidence, Mortality and Prevalence Worldwide IARC CancerBase No. 5, version 2.0 IARCPress, Lyon, 2004.

Further Information:

- Roche in Oncology: www.roche.com/pages/downloads/company/pdf/mboncology05e_b.pdf <http://www.roche.com/pages/downloads/company/pdf/mboncology05e_b.pdf>

- Lymphoma: www.lymphoma-net.org <http://www.lymphoma-net.org/>

- The Lymphoma Coalition: www.lymphomacoalition.org <http://www.lymphomacoalition.org/>

- Cancer: www.health-kiosk.ch/start_krebs.htm <http://www.health-kiosk.ch/start_krebs.htm>

- World Health Organization: www.who.int <http://www.who.int/>

For more information, please contact:

Robert Purcell Amber Bradbury

Roche Ketchum

Robert.purcell@roche.com

+41 61 688 0846 +44 207 611 3842

Aviva Grisby Senior Account Executive Ketchum 35-41 Folgate Street London E1 6BX Tel: +44 (0) 20 7611 3686 Fax: +44 (0) 20 7611 3850 Ketchum. Passion and Precision in Communication.


'"/>




Related medicine technology :

1. MabThera Significantly Extends Survival And Cures More Patients With Aggressive Lymphoma Than Chemotherapy Alone
2. Innovative Cancer Drug MabThera Again Shown To Improve Survival Rates In Patients With Lymphoma
3. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
4. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
5. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
6. Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to a Current Standard of Care
7. Next Safety, Inc.s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery
8. Ivivis PEMF Technology Significantly Improves Neuron Survival in Parkinsons Disease Model, Study Finds
9. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
10. The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
11. Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology ... outcomes platform, Bracket eCOA (SM) 6.0, at the 52 ... 30, 2016 in Philadelphia , Pennsylvania.  A ... product of its kind to fully integrate with RTSM, will ... 6.0 is a flexible platform for electronic clinical outcomes assessments ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... environments  Oticon , industry leaders in ... the launch of Oticon Opn ™, the world,s ... world of possibilities for IoT devices.      ... Opn, Oticon introduces a number of ,world firsts,: ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media with ... X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color ... users can now reveal the media of their split screens with growing colorful ...
(Date:6/27/2016)... ... 2016 , ... A revolution is underway. Brooklyn-based company, ... for the millions of people who require these medical transport services annually. ... the use of technology. Now, SmartEMS has put forth an industry-changing app that ...
(Date:6/26/2016)... ... 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic treatment ... Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. This ... of the world’s leading providers of cereal and other breakfast foods. Its residents often ...
(Date:6/26/2016)... ... ... blind and certified personal trainer is helping to develop a weight loss fitness plan that ... the two major problems leading the fitness industry today:, , All ... They don’t eliminate all the reasons people quit their exercise program , ...
(Date:6/25/2016)... ... 25, 2016 , ... Austin residents seeking Mohs surgery services, can now turn ... to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization ... selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction ...
Breaking Medicine News(10 mins):